4d Pharma PLC 4D asthma publication
August 14 2018 - 1:01AM
RNS Non-Regulatory
TIDMDDDD
4d Pharma PLC
14 August 2018
4D pharma plc
(the "Company" or "4D")
Publication of data in connection with MRx0004
4D announces publication of data highlighting ability of MRx0004
to protect against airway inflammation in severe asthma
Data suggests that MRx0004 is a promising next-generation
therapeutic for management of asthma
14 August 2018 - 4D pharma plc (AIM: DDDD), a pharmaceutical
company leading the development of live biotherapeutics, today
announces the publication of a paper demonstrating that MRx0004, a
live biotherapeutic derived from the human gut microbiome, can
protect against airway inflammation by reducing both neutrophilic
and eosinophilic infiltration in a mouse model of severe
asthma.
The paper "Bifidobacterium breve MRx0004 protects against airway
inflammation in a severe asthma model by suppressing both
neutrophil and eosinophil lung infiltration" (Raftis et al.) is
published in the Nature Publishing Group journal Scientific
Reports.
Asthma is a phenotypically heterogeneous disease. Between 5 and
10 % of asthma patients have a severe form of the disease which is
refractory to steroid treatment and whose symptoms cannot be
controlled despite the application of high-intensity treatments. In
severe asthma, airway inflammation can be predominantly
eosinophilic, neutrophilic, or mixed and patients presenting with
neutrophilic inflammation have particularly poor treatment options.
Severe asthma is estimated to account for more than 60 % of
asthma-associated healthcare costs.
MRx0004 is a strain of Bifidobacterium breve isolated from the
gut microbiome of a healthy human. It was tested prophylactically
and therapeutically in a house dust mite mouse model of severe
asthma. A strong reduction of neutrophil and eosinophil
infiltration was observed in lung bronchoalveolar lavage fluid
(BALF) following MRx0004 treatment. Furthermore, MRx0004 had a
striking effect on lung histopathology, with a strong reduction of
both peribronchiolar and perivascular inflammatory infiltrate. The
efficacy of MRx0004 exceeded that of the anti-IL-17 positive
control used in the experiment.
Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented:
"This data provides further evidence that live biotherapeutics have
the potential to change the way we treat disease. Using MRx0004, we
have demonstrated superior efficacy to biologics in a severe and
steroid-resistant model of asthma."
He added: "Perhaps more significantly, we have shown that
MRx0004 can strongly reduce neutrophil and eosinophil airway
infiltration concurrently. This is something which is not
achievable with current therapies and is further evidence of the
potential of MRx0004 as a next-generation therapeutic for the
management of asthma."
Please find a copy of the paper here:
http://www.nature.com/articles/s41598-018-30448-z
For further information please contact:
4D + 44 (0)113 895 0130
Duncan Peyton, Chief Executive Officer
Zeus Capital Limited - Nomad and Joint Broker
Dan Bate / Jordan Warburton +44 (0) 161 831 1512
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson
Phil Walker
About 4D
Founded in February 2014, 4D is a world leader in the
development of live biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacteria, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform that rationally identifies novel bacteria that
have a precise and evolved therapeutic effect. All of 4D's live
biotherapeutic products are orally delivered single strains of
bacteria that are naturally found in the healthy human gut. 4D has
completed a phase I study in Irritable Bowel Syndrome and has
completed dosing in a phase I study in Paediatric Crohn's Disease.
It currently has a pipeline of 13 pre-clinical programmes, covering
disease areas such as cancer, poorly controlled asthma, autoimmune
and CNS disease, and plans to commence four additional clinical
studies in 2018. For more information, refer to
https://www.4dpharmaplc.com/.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFEETFIVLIT
(END) Dow Jones Newswires
August 14, 2018 02:01 ET (06:01 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024